Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Expert consensus recommendations on appropriate serological testing for the chief complaint of alopecia
Middleton, Hayden T. , Monahan, Erin, James, Garland, Grippe, Kristen, Link, Jenny L. , Chavez, Magdalena, Sominidi‐Damodaran, Sindhuja , Pham, Van Trọng, Franley, Brittney, O’Brien, Jack C. , Whinery, Sarah Jane, James, Garland, Chavez, Magdalena, Pham, Van, Griffith, Cynthia Faires

Mayo Clinic

Journal of Dermatology for Physician Assistants | August 22, 2025 | Volume: 19 | Issue: 3 | Pages: 6-13

10.1097/jdpa.0000000000000067 Get It

Study Design: A panel of 13 clinicians with experience in dermatology and primary care was assembled to review literature regarding the diagnostic workup of scarring and nonscarring alopecias. The literature for review included clinical trials, meta-analyses, systematic reviews, and previously published guidelines from the last 10 years. After review, the panel drafted a list of consensus statements and then voted on these statements using a modified eDelphi method in order to verify the validity and clarity of each statement. Objective: Our objective, as a panel, was to formulate a clear set of guidelines in the workup of various forms of hair loss by a systematic review of clinical data and literature on the matter. Background: Hair loss is a common and frustrating medical concern for patients worldwide and accounts for significant health care utilization and cost. Moreover, hair loss may present as a symptom of an underlying medical condition requiring attention and treatment. Results: After review, the panel reached a total of 22 consensus statements regarding recommendations for diagnostic testing in the setting of hair loss, 17 of those statements focused on nonscarring alopecias, and 5 statements directed toward scarring alopecias. The statements were evaluated by members of the panel and voted on through a modified eDelphi method and discussed in an open forum. Conclusion: The panel’s review revealed that the diagnostic laboratories and/or scalp biopsy should be considered to varying degrees depending on the type of hair loss at presentation. If there is concern for a scarring process, a biopsy should be strongly considered, while serum laboratory work may be of little benefit. In nonscarring alopecias including alopecia areata, telogen effluvium, and androgenetic alopecia, the literature supports ordering certain serologic tests based on the type of hair loss at presentation.
Feasibility of a Shock Simulation with Ultrasound Curriculum
Lee, Sarah , Alsunaid, Sammar , Ganti, Subramanya Shyam , Durairajan, Navin, Mohamed, Abdelaziz , Shiari, Aryan , Venkat, Divya , Sankari, Abdulghani , Lee, Sarah J , Ganti, Shyam , Venkat, Divya , Shiari, Aryan , Mohamed, Abdelaziz

Mayo Clinic

ATS Scholar | August 20, 2025 | Volume: 6 | Issue: 3 | Pages: 287-291

10.34197/ats-scholar.2024-0054br | PMID 40833479 Get It

Investigating Speech Intelligibility Capabilities of Electrical Auditory Stimulation
Kingsbury, Sarah , Cevette, Michael J. , Kingsbury, Sarah E , Stepánek, Jan , Pradhan, Gaurav N , Stepánek, Jan , Pradhan, Gaurav N.

Mayo Clinic

Military Medicine | August 19, 2025 | Volume: 191 | Issue: 3-4 | Pages: e592-e600

10.1093/milmed/usaf430 | PMID 40899906 Get It

Abstract Introduction In military settings, ear-worn communication systems and hearing protection have equal importance, but opposite purposes. It is crucial to provide clear communication signal free of noise that may also be hazardous to hearing. Electrical auditory stimulation is a mode of transmitting high fidelity speech information with an amplitude modulated electromagnetic signal that is sent transcutaneously through electrodes. No traditional ear-worn transducer is needed, offering various locations for receiving auditory information on the head and body. The purpose of the current study is to evaluate the speech intelligibility at different locations on the head and body in quiet and noise. Materials and Methods Fifty participants total took part in this study with Mayo Clinic IRB approval and informed consent. All completed a pure-tone air conduction hearing test verifying normal hearing. In the first experiment, 20 participants completed electrical word recognition testing in quiet at 3 unique locations using 16-item Modified Rhyme Test (MRT) recordings transmitted through a Tonndorf Audimax Model 500 Audiometer in a repeated measures counter-balanced design. In the second experiment, 30 participants completed testing in quiet as well as in background noise at 3 mastoid-anchored locations, using 68-70 dBA of pink noise presented in the sound field through an immersive Spatial Reality sound system. One-way repeated-measures ANOVA was used for comparing the transformed percent MRT scores between 3 locations on the head, followed by the pairwise comparison of the post-hoc analysis using the t-test. For the second experiment, 2-way repeated-measures ANOVA was used to detect the main effects (location and condition) and interaction, followed by multiple comparisons using paired t-tests. Results The percent correct score on the modified MRT tests at the mastoid location during electrical hearing stimulation was statistically significantly greater than at the neck location. Three placements that all had at least one mastoid electrode placement (bilateral mastoid, wrist, and neck) produced very similar MRT scores in a quiet environment. The 2-way repeated measures ANOVA performed on the transformed MRT percent scores showed a significant main effect because of the condition (quiet vs. noise) but did not reveal any significant effect of location. MRT percent correct scores in the noisy condition at all 3 locations were statistically significantly lower than in the quiet condition. All average percent correct scores were greater than 80% in noise. Conclusions Non-acoustic transcutaneous electrical stimulation of the cochlea was shown to perform well in both quiet and noisy environments opening opportunities for future implementations that will help safeguard hearing by decreasing the risk of acoustic damage although maintaining excellent word recognition. Clinical Trial Registration Identifier: NCT05112809.
Differences in neuropsychological performance across clinical variants of progressive supranuclear palsy
Boots, Elizabeth A. , Weigand, Stephen D. , Pham, Nha Trang Thu, Ali, Farwa , Stierwalt, Julie A. G., Boland, Sarah, Stephens, Yehkyoung C. , Josephs, Keith A. , Whitwell, Jennifer L., Stierwalt, Julie A, Boland, Sarah M, Machulda, Mary M , Boots, Elizabeth A , Clark, Heather M. , Botha, Hugo , Whitwell, Jennifer , Machulda, Mary M.

Mayo Clinic

Journal of the International Neuropsychological Society | August 18, 2025 | Volume: 31 | Issue: 5-6 | Pages: 384-395

10.1017/s1355617725101215 | PMID 40820613 Get It

Abstract Objective: We investigated differences in cognition between variants of progressive supranuclear palsy (PSP) including PSP-Richardson (PSP-RS) and subcortical and cortical variants using updated diagnostic criteria and comprehensive neuropsychological assessment. Method: We recruited 140 participants with PSP (age = 71.3 ± 6.9 years; education = 15.0 ± 2.8 years; 49.3% female) who completed neurological and neuropsychological assessment. Participants received diagnoses of PSP clinical variants at their evaluation (or retrospectively if evaluated before 2017) according to the Movement Disorder Society PSP criteria. We grouped variants as PSP-RS (62 participants), PSP-Cortical (25 with PSP-speech/language and 9 with PSP-corticobasal syndrome), and PSP-Subcortical (27 with PSP-parkinsonism, 11 with PSP-progressive gait freezing, and 6 with PSP-postural instability). Analysis of covariance adjusted for age assessed for differences in neuropsychological performance between variants across cognitive domains. Results: PSP-Cortical participants performed worst on measures of visual attention/working memory (Spatial Span Forward/Backward/Total), executive function (Frontal Assessment Battery), and language (Letter Fluency). PSP-RS participants performed worst on verbal memory (Camden Words). There were no significant group differences for the MoCA or indices of visuospatial function. There were no sex or education differences between PSP groups; however, there were differences in age at visit and disease duration. Conclusions: In a large sample of participants with PSP, there were differences in cognition across PSP-RS, PSP-Subcortical, and PSP-Cortical variants, with PSP-Cortical and, to a lesser extent, PSP-RS, performing worse on tests of attention and executive function. These findings suggest cognitive distinctions among PSP clinical variants and highlight the value of neuropsychological assessment in differential diagnosis of PSP subtypes for more accurate and timely clinical classification.
Dose individualisation of antibiotics in critically ill patients with inflammation: A narrative review
Dräger, Sarah , Minichmayr, Iris K. , Alipanah, Narges , Frazee, Erin N. , Bos, Lieuwe D. J. , Fleuren, Lucas M. , Hunfeld, Nicole , Mathew, Sumith K. , Stocker, Sophie L. , Torres, Antoni , Alipanah-Lechner, Narges , Frazee, Erin N , Hunfeld, Nicole G M , Telles, João Paulo , Torres, Antoni , Koch, Birgit C P , Endeman, Henrik

Mayo Clinic

British Journal of Clinical Pharmacology | August 15, 2025 | Volume: 91 | Issue: 11 | Pages: 3042-3053

10.1002/bcp.70185 | PMID 40813897 Get It

Due to extensive pathophysiological changes in critically ill patients, standard dosing of antibiotics may lead to inadequate drug exposure. This is concerning, as insufficient plasma drug concentrations may lead to treatment failure, whereas excessive drug exposure may increase the risk of toxic adverse events. The role of inflammation as a factor influencing the pharmacokinetics (PK) and pharmacodynamics (PD) of antibiotics remains largely unknown. PK/PD target attainment of antibiotics can be improved through therapeutic drug monitoring, i.e., measurement of drug concentrations in the blood with subsequent dosage adjustment to reach a certain target. Besides, population PK models may be used to predict drug exposure and tailor dosing in an individual patient (model‐informed precision dosing). Inflammatory biomarkers have been proposed to measure inflammation levels and guide antibiotic treatment. However, their potential to guide antibiotic dosing is unclear. This narrative review describes associations between inflammation and PK/PD of antibiotics in critically ill patients, and the role of biomarkers, therapeutic drug monitoring and model‐informed precision dosing in improving antibiotic dosing. A focus of future research should be on the interplay between inflammation and PK/PD of antibiotics by including inflammatory biomarkers in PK/PD models and using big data to predict antibiotic exposure in critically ill patients.
Representation of Skin of Color in Cutaneous Oncology Publications: A Decade of Trends and Disparities
Amjad, Sarah , Cravero, Karen , Marks, Lisa , Degesys, Catherine A. , Barbosa, Naiara S. , Amjad, Sarah A , Marks, Lisa A

Mayo Clinic

International Journal of Dermatology | August 14, 2025 | Volume: 65 | Issue: 4 | Pages: 813-815

10.1111/ijd.70011 | PMID 40928140 Get It

Functional Characterization of Two Novel Biallelic PIGV Variants in a Patient With Myoclonic Seizures and Elevated Alkaline Phosphatase: A Case Report
Wilke, Matheus Vernet Machado Bressan , Verheijen, Johannes M., Umeshita, Saori, Thurman, Sarah Allen, Darr, Kahlen , Klee, Eric W. , Schimmenti, Lisa A. , Panwar, Deepak , Klee, Eric, Schimmenti, Lisa A , Vairo, Filippo , Wilke, Matheus V M B , Panwar, Deepak, Verheijen, Johannes M., Thurman, Sarah , Nickels, Katherine , Murakami, Yoshiko , Vairo, Filippo Pinto e

Mayo Clinic

American Journal of Medical Genetics Part A | August 13, 2025 | Volume: 200 | Issue: 1 | Pages: 171-177

10.1002/ajmg.a.64220 | PMID 40799153 Get It

ABSTRACT Post‐translational modifications, such as glycosylation and phosphorylation, play a critical role in protein trafficking, interactions, and stability. Disruptions in these pathways can lead to glycosylphosphatidylinositol (GPI) deficiencies, which present with a spectrum of clinical features, including congenital anomalies, dysmorphic features, developmental delay, hypotonia, and epilepsy. Biallelic variants in PIGV , a key mannosyltransferase in GPI biosynthesis, cause Hyperphosphatasia with Impaired Intellectual Development Syndrome 1 (HPMRS1), a rare disorder characterized by hyperphosphatasia, seizures, developmental delay, hypotonia, abnormal MRI findings, and distinct facial dysmorphisms. Fewer than 30 cases have been reported to date. We conducted a case study and literature review; with clinical data obtained from medical records. A 2‐year‐old female presented with developmental delay, myoclonic epilepsy, hypotonia, and mild facial dysmorphism. Laboratory results showed elevated alkaline phosphatase (899 U/L) and low pyridoxal 5′‐phosphate levels in cerebrospinal fluid (CSF). Brain MRI revealed diffuse cerebral volume loss and ventriculomegaly. Trio genome sequencing identified two PIGV variants: c.1415T>C‐p.(Leu472Pro) and c.524T>C‐p.(Leu175Pro). Functional studies using PIGV ‐knockout HEK293 cells transfected with wild‐type or mutant PIGV constructs demonstrated reduced GPI‐anchored protein (GPI‐AP) expression under weaker promoters, indicating impaired enzymatic activity. We report two novel PIGV variants associated with HPMRS1, emphasizing the value of functional assays in variant interpretation. Our findings also highlight the diagnostic relevance of alkaline phosphatase measurement in patients with refractory seizures.
A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death–Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma
Kourelis, Taxiarchis , Ailawadhi, Sikander , Vogl, Dan T. , Gibson, Sarah E. , Sharik, Meaghen E. , Du, Megan T. , Ames, Tyler D. , Yim, Christina Y. , Baeck, Johan , Price, Matthew R. , Jimeno, J. , Chesi, Marta , Jimeno, Jose M , Bergsagel, P. Leif , Ailawadhi, Sikander , Gibson, Sarah E , Bergsagel, P. Leif

Mayo Clinic

Clinical Cancer Research | August 12, 2025 | Volume: 31 | Issue: 21 | Pages: 4518-4528

10.1158/1078-0432.ccr-24-2574 | PMID 40795066 Get It

Abstract Purpose: R,R-1,2 cyclohexanediamine-pyrophosphato-platinum(II) (PT-112) is a novel immunogenic cell death–inducing small molecule under phase II development in several cancer types. It inhibits ribosome biogenesis and causes organelle stresses, leading to selective immunogenic cell death in cancer cells. The possibility of PT-112’s pyrophosphate moiety driving high drug concentrations to bone sites of disease has led to an interest in PT-112’s use in multiple myeloma. In this study, we present findings from phase I and in vivo studies for PT-112 in relapsed or refractory multiple myeloma. Experimental Design: PT-112 biodistribution was analyzed in mice via laser ablation inductively coupled plasma mass spectrometry. The activity of PT-112 was assessed in de novo and transplantable Tg(Igkv3-5*-MYC)#Plbe (Vk*MYC) multiple myeloma mouse models as monotherapy or combination therapies. M-spike levels and survival were measured. A phase I dose escalation study of PT-112 monotherapy was conducted using a 3 + 3 design in patients with heavily pretreated relapsed or refractory multiple myeloma with exhausted available therapies. Results: In vivo biodistribution imaging revealed high concentrations in the bone, kidney, lung, skin, and liver. PT-112 was active in Vk*MYC multiple myeloma mouse models, both alone and in combination. Phase I data showed that PT-112 monotherapy was safe and well-tolerated, establishing a recommended phase II dose of 360 mg/m2 on days 1, 8, and 15 of a 28-day cycle. Confirmed responses and other signals of activity were observed. Conclusions: These results suggest a lack of cross-resistance with the standard of care and support the translational value of the Vk*MYC model system. Further clinical investigation of PT-112 is warranted in multiple myeloma.
Identifying diagnostic errors in the emergency department using trigger-based strategies
Khalili, Mahsa , Enayati, Moein , Patel, Shrinath, Huschka, Todd R., Parker, Sarah J. , Mahajan, Prashant , Bellolio, Fernanda , Huschka, Todd, Cabrera, Daniel , Parker, Sarah J , Mahajan, Prashant , Bellolio, M Fernanda , Cabrera, Daniel , Pasupathy, Kalyan S.

Mayo Clinic

BMJ Open Quality | August 7, 2025 | Volume: 14 | Issue: 3 | Pages: e003389

10.1136/bmjoq-2025-003389 | PMID 40774723 Get It

Importance Diagnostic errors represent a major patient safety concern, with the potential to significantly impact patient outcomes. To address this, various trigger-based strategies have been developed to identify diagnostic errors, aiming to enhance clinical decision-making and improve patient safety. Objective To evaluate the performance of three pre-established triggers (T) in the emergency department (ED) setting and assess their effectiveness in detecting diagnostic errors. Design Consecutive cohort, retrospective observational design. Setting Academic ED with 80 000 annual visits. Participants Adults and children presenting to a single ED in the USA between 1 May 2018 and 1 January 2020. Intervention/outcomes Electronic health records (EHRs) were retrieved and categorised into trigger-positive and trigger-negative cases using the following criteria: T1—unscheduled returnvisits to the ED with admission within 7–10 days of theinitial visit; T2—care escalation from the inpatient unitto the intensive care unit (ICU) within 6, 12 or 24 hoursof ED admission; and T3—all deaths in the ED or within24 hours of ED admission, excluding palliative care. A random sample of trigger-positive cases was reviewed using the SaferDx tool to determine the presence or absence of a diagnostic error. Results A total of 5791 trigger-positive and 118262 trigger-negative cases were identified. Among trigger-positive cases, 4159 (72%) were associated with T1, 1415 (24%) with T2, and 217 (4%) with T3. A preliminary chart review of 462 trigger-positive and 251 trigger-negative cases showed most were error-negative (279 and 217, respectively). Detailed reviews found 32 diagnostic errors among 183 trigger-positive cases, yielding PPVs of 5.4% (T1), 8.9% (T2), and 6.9% (T3). No errors were found in 34 reviewed trigger-negative cases, resulting in a 100% NPV. Sepsis was the most common diagnosis among error-positive cases (n=11, 34.4%). Those with non-specific chief complaints like altered mental status or shortness of breath had higher diagnostic error risk. Conclusion and relevance While previously proposed EHR-based triggers can identify some diagnostic errors, they are insufficient for detecting all cases. To improve error detection performance, we recommend exploring data-driven strategies, such as machine learning techniques, to more effectively identify underlying contributing factors to diagnostic errors and enhance detection accuracy in the ED.